DEAN NICHOLAS M.,FOULKES J. GORDON,O&rsquoDONNELL NIALL,BENNETT C. FRANK,FREIER SUSAN M.
申请号：
NZ60166009
公开号：
NZ601660A
申请日:
2009.08.25
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
601660 Disclosed is a compound which comprises a modified oligonucleotide consisting of 12 -30 linked nucleosides, at least a 12 nucleobase sequence portion of which is complementary to nucleotides within the region selected from nucleotides 718-751, 1388-1423, 2728-2797, 1394-1423, 1659-1689, 2100-2129 and 1399-1423 of SEQ ID NO: 9, wherein the modified oligonucleotide comprises (a) a gap segment consisting of linked deoxynucleosides (b) a 5&rsquo wing segment consisting of linked modified nucleosides and (c) a 3&rsquo wing segment consisting of linked modified nucleosides wherein the gap segment is positioned between the 5&rsquo wing segment and the 3&rsquo wing segment and wherein each modified nucleoside within each wing segment comprises a modified sugar. Further disclosed is a compound which comprises a modified oligonucleotide consisting of 12 - 30 linked nucleosides, at least a 12 nucleobase sequence portion of which is complementary to nucleotides within the region selected from nucleotides 1457-1689, 2120-2147,2267-2301,553-611,1469-1508 and 1559-1605 of SEQ ID NO: 9, wherein the modified oligonucleotide comprises (a) a gap segment consisting of linked deoxynucleosides (b) a 5&rsquo wing segment consisting of linked modified nucleosides and (c) a 3&rsquo wing segment consisting of linked modified nucleosides wherein the gap segment is positioned between the 5&rsquo wing segment and the 3&rsquo wing segment and wherein each modified nucleoside within each wing segment comprises a modified sugar and wherein the compound demonstrates at least 60% inhibition in a human connective tissue growth factor expression assay.
